Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-1
NCT04886804Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 18
01
Overview
Phase 1, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) and solid tumor (10 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Dose Limiting Toxicities at 12 months and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04886804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886804.